3 results on atopic dermatitis
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
Primary: (part 3) Potential of BPR277 1% ointment b.i.d. to improve the clinical severity of lesional skin in the majority of NS patients at end of treatment versus baseline of >= 2 points, dose range and regimen relationship on clinical…
The objectives of this follow-up/extension study of the VIPES study are:• To assess the efficacy of Viaskin® Peanut after up to 36 months of Epicutaneous Immunotherapy (EPIT) in peanut-allergic subjects.• To evaluate the safety of long-term…